Key result
TSP-derived angiostatic peptides appear as potent and promising therapeutic agents in anti-angiogenic therapy, overcoming the poor bioavailability of full-length thrombospondin molecules.
TSP-derived peptides show promise as anti-angiogenic therapeutic agents in preclinical cancer models due to better bioavailability than full-length thrombospondins.
No takes yet. Share an insight, caveat, or question.
Supports preclinical promise of TSP peptides for anti-angiogenesis; leaves open clinical translation pending prospective trials.
Vailhé et al. (2003) conducted a review in Cancer / Angiogenesis. Thrombospondin-1 (TSP-1), TSP-2, and derived peptides was evaluated. TSP-derived angiostatic peptides appear as potent and promising therapeutic agents in anti-angiogenic therapy, overcoming the poor bioavailability of full-length thrombospondin molecules.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: